These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 28970217

  • 21. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL, Koelmeyer R, Kandane-Rathnayake R, Golder V, Hoi A, Huq M, Hammond E, Nab H, Nikpour M, Morand EF.
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [Abstract] [Full Text] [Related]

  • 22. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D, Hao Y, Mu L, Xie W, Fan Y, Ji L, Zhang Z.
    Rheumatology (Oxford); 2020 Nov 01; 59(11):3400-3407. PubMed ID: 32337549
    [Abstract] [Full Text] [Related]

  • 23. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y, Ji L, Gao D, Fan Y, Geng Y, Zhang X, Li G, Zhang Z.
    Lupus Sci Med; 2022 Mar 01; 9(1):. PubMed ID: 35241499
    [Abstract] [Full Text] [Related]

  • 24. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G.
    Ann Rheum Dis; 2024 Mar 12; 83(4):464-474. PubMed ID: 38233103
    [Abstract] [Full Text] [Related]

  • 25. Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
    Golder V, Kandane-Rathnayake R, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Nikpour M, Hoi A, Morand EF, Asia Pacific Lupus Collaboration.
    J Rheumatol; 2024 Aug 01; 51(8):790-797. PubMed ID: 38490668
    [Abstract] [Full Text] [Related]

  • 26. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
    Wahadat MJ, van den Berg L, Timmermans D, van Rijswijk K, van Dijk-Hummelman A, Bakx S, Verkaaik M, Versnel MA, Kamphuis S.
    Lupus Sci Med; 2021 Dec 01; 8(1):. PubMed ID: 34969874
    [Abstract] [Full Text] [Related]

  • 27. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A.
    Arthritis Rheumatol; 2020 Aug 01; 72(8):1314-1324. PubMed ID: 32275125
    [Abstract] [Full Text] [Related]

  • 28. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
    Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Kaneko Y, Takeuchi T.
    Rheumatology (Oxford); 2022 Aug 30; 61(9):3777-3791. PubMed ID: 35015824
    [Abstract] [Full Text] [Related]

  • 29. Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.
    Babaoğlu H, Li J, Goldman D, Magder LS, Petri M.
    Arthritis Care Res (Hoboken); 2020 Feb 30; 72(2):225-232. PubMed ID: 31507071
    [Abstract] [Full Text] [Related]

  • 30. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.
    Semin Arthritis Rheum; 2018 Dec 30; 48(3):467-474. PubMed ID: 29555348
    [Abstract] [Full Text] [Related]

  • 31. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study.
    Connelly K, Kandane-Rathnayake R, Hoi A, Louthrenoo W, Hamijoyo L, Cho J, Lateef A, Fen Luo S, Wu YJ, Li Z, Navarra S, Zamora L, Sockalingam S, Hao Y, Zhang Z, Katsumata Y, Harigai M, Oon S, Chan M, Chen YH, Bae SC, O'Neill S, Goldblatt F, Kikuchi J, Takeuchi T, Ling Ng KP, Tugnet N, Basnayake BMDB, Ohkubo N, Tanaka Y, Sing Lau C, Nikpour M, Golder V, Morand EF, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2022 Dec 30; 4(12):e831-e841. PubMed ID: 38261391
    [Abstract] [Full Text] [Related]

  • 32. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort.
    Saccon F, Zen M, Gatto M, Margiotta DPE, Afeltra A, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Frontini G, Moroni G, Dall'Ara F, Tincani A, Signorini V, Mosca M, Frigo AC, Iaccarino L, Doria A.
    Ann Rheum Dis; 2020 Jul 30; 79(7):943-950. PubMed ID: 32321721
    [Abstract] [Full Text] [Related]

  • 33. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M, Magder LS.
    Arthritis Rheumatol; 2018 Nov 30; 70(11):1790-1795. PubMed ID: 29806142
    [Abstract] [Full Text] [Related]

  • 34. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
    Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Yu D, Karyekar CS, Sing Lau C, Monk JA, Nikpour M, Hoi A, Morand EF, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2022 Dec 30; 4(12):e822-e830. PubMed ID: 38261390
    [Abstract] [Full Text] [Related]

  • 35. Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus.
    Elefante E, Tani C, Stagnaro C, Signorini V, Parma A, Carli L, Zucchi D, Ferro F, Mosca M.
    Arthritis Res Ther; 2020 Oct 14; 22(1):241. PubMed ID: 33054823
    [Abstract] [Full Text] [Related]

  • 36. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA, Truglia S, Miranda F, Spinelli FR, Alessandri C, Valesini G.
    Lupus; 2016 Jun 14; 25(7):719-26. PubMed ID: 26821965
    [Abstract] [Full Text] [Related]

  • 37. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study.
    Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, Cho J, Lateef A, Hamijoyo L, Navarra SV, Zamora L, Sockalingam S, An Y, Li Z, Katsumata Y, Harigai M, Hao Y, Zhang Z, Kikuchi J, Takeuchi T, Basnayake BMDB, Chan M, Ng KPL, Tugnet N, Kumar S, Oon S, Goldblatt F, O'Neill S, Gibson KA, Ohkubo N, Tanaka Y, Bae SC, Lau CS, Nikpour M, Golder V, Morand EF, Asia-Pacific Lupus Collaboration.
    Arthritis Res Ther; 2022 Mar 14; 24(1):70. PubMed ID: 35287720
    [Abstract] [Full Text] [Related]

  • 38. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.
    Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gómez-Puerta JA, Catoggio LJ, Alvarellos A, Saurit V, Borba E, Sato E, Costallat L, Da Silva NA, Iglesias-Gamarra A, Neira O, Reyes-Llerena G, Cardiel MH, Amigo MC, Acevedo-Vásquez E, Esteva-Spinetti MH, Alarcón GS, Pons-Estel BA.
    J Rheumatol; 2019 Oct 14; 46(10):1299-1308. PubMed ID: 30824636
    [Abstract] [Full Text] [Related]

  • 39. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN, Saraiva L, Jesus D, Doria A, da Silva JP, Inês LS.
    Rheumatology (Oxford); 2023 Nov 02; 62(11):3627-3635. PubMed ID: 36847423
    [Abstract] [Full Text] [Related]

  • 40. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study.
    Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Li ZG, Hoi A, Nikpour M, Morand EF, Asia-Pacific Lupus Collaboration.
    Lancet Rheumatol; 2019 Oct 02; 1(2):e95-e102. PubMed ID: 38229349
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.